Obermatt

Cigna

NYQ:CI · US1255231003
Health Care Providers & ServicesXX-Large

360

59
EV / EBIT82
Price / Owner Earnings56
Owner Earnings Yield88
Dividend Yield100
Price/Sales100
EV / Gross Profit71
Price/Book67
Return on Capital84
Cash Return on Capital80
Return on Equity84
EBIT Margin45
Gross Profitability23
Cash Conversion16
Accruals22
Owner Earnings Margin45
Sales growth51
Profit Growth100
Long-Term EPS Growth39
Owner Earnings Growth60
Reinvestment90
Price momentum33
Debt load24
Refinancing4
Debt Payback61
Liquidity89
Analyst ratings16
Opinion Changes38
Price Target Upside41
Market mood15
Value Creation18/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Cigna generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryUSA
IndustryHealth Care Providers & Services
SizeXX-Large
TypePublic Company
ExchangeNYSE
Founded1981
Employees24,452
ISINUS1255231003
Last UpdateApr 2, 2026
Themes
Chronic DiseasesCorporate Wellness ProgramsPharmacovigilanceHealth DiagnosticsEmployee Assistance Program (EAP)Employee BenefitsDigital WellnessDigital Mental HealthHealth CareMedical

Description

The Cigna Group, together with its subsidiaries, operates as a global health company. Segments The company operates in two segments: Evernorth Health Services and Cigna Healthcare. The Evernorth Health Services segment, through its Pharmacy Benefit…

Analysis

Bargain bin

The Cigna Group is priced cheaply, and that invites the natural question of why, since the underlying business scores below average. Worth noting: the cash the business generates has lagged behind what the income statement shows.

On valuation, the picture is attractive. The owner-earnings multiple stands at 11.3×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around -1% a year, against analyst forecasts of 10%. The price, in other words, assumes less than the experts do.

Growth is tepid; the safety picture is sturdy. The company scores 18/20 on our value-creation score: strong value creator.

Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
79
2023202420252026

All-time high

98

Jan 2026

All-time low

78

Feb 2026

Average rank

93

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
100
83
82
95
Price/Earnings
13
90
80
97
Price/Book
67
55
59
72
Dividend Yield
100
90
89
87
Value (overall)
98
98
95
98

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Cigna with its peers
Larimar Therapeutics
NMQ:LRMR
26
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Soleno Therapeutics
NAQ:SLNO
67
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Extendicare
TOR:EXE
93
CountryCanada
IndustryHealth Care Providers & Services
SizeMedium
Full Stock Analysis →
Coeptis Therapeutics
NAQ:COEP
27
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Recursion Pharmaceuticals
NSQ:RXRX
20
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Protagonist Therapeutics
NMQ:PTGX
27
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →